A number already in your chart may hold clues
You've probably had a complete blood count done at some point — a standard test most doctor visits include.
Hidden in that report is a simple math clue called the neutrophil-to-lymphocyte ratio, or NLR (a ratio of two white blood cell counts that can reflect inflammation).
For people fighting advanced head and neck cancer, that tiny number may help predict how well treatment will work.
Head and neck squamous cell carcinoma (HNSCC) is one of the most challenging cancers to treat when it comes back or spreads.
Current options include immunotherapy (drugs that help the immune system attack cancer) and targeted therapies like cetuximab, which blocks a growth signal on tumor cells.
Combining these has shown promise. But not every patient benefits — and right now, doctors don't have a reliable way to tell in advance who will respond.
The old way vs. the new clue
Doctors already track one tumor marker called PD-L1 to help choose immunotherapy patients.
But PD-L1 testing requires tissue and doesn't always predict outcomes accurately.
Here's what's different this time: researchers zoomed in on something already available in almost every routine blood test — the ratio between neutrophils and lymphocytes — and asked whether it could do some of that predictive work, simply and cheaply.
How it works, in simple terms
Think of the immune system as a neighborhood.
Neutrophils are the first responders — quick, aggressive, but not always precise.
Lymphocytes are the specialists — including the T cells that immunotherapy relies on to attack cancer.
A high NLR means too many first-responder alarms and not enough specialists. A low NLR suggests a better-organized defense — one more likely to work with immunotherapy instead of fighting against it.
The study at a glance
Researchers analyzed blood samples from patients in a Phase 2 clinical trial (NCT03370276) that tested cetuximab plus nivolumab in recurrent or metastatic HNSCC.
They measured NLR in the blood at two time points: baseline (before treatment) and one month after starting therapy. They also measured tumor-tissue NLR by staining immune cells in the primary tumor.
Then they compared outcomes — survival, progression-free time, and overall response — between high- and low-NLR groups.
The baseline blood NLR didn't predict much on its own.
But the on-treatment NLR — the ratio measured after one month of therapy — was a strong signal. Patients with a low on-treatment NLR lived significantly longer and their disease stayed controlled significantly longer.
In numbers you can feel: patients with a low on-treatment NLR had about a third of the risk of dying and less than half the risk of their disease progressing compared to those with a high on-treatment NLR.
Low tumor-tissue NLR before treatment also predicted better response — suggesting the balance of immune cells inside the tumor matters too.
This doesn't mean you should rush out to ask for an NLR test.
It means researchers have identified a promising, easy-to-measure signal that deserves more study.
Why this is more interesting than it sounds
Most cancer biomarkers require expensive tests or tissue samples.
NLR is essentially free. It's calculated from a standard blood panel that any clinic can run.
If confirmed in larger trials, it could help doctors monitor how well treatment is working early — and consider changing course sooner for patients whose NLR stays high.
This adds to growing evidence that systemic inflammation shapes how well immunotherapy works.
Other studies in lung cancer and melanoma have found similar patterns. The fact that NLR shows up again in head and neck cancer supports the idea that inflammation may be a common enemy of effective immune attack — no matter where the tumor is.
If you or a loved one is being treated for recurrent or metastatic head and neck cancer, ask your oncologist how they interpret your blood counts.
NLR isn't a standalone decision-maker today. It's one more piece of context that, in the near future, could help guide discussions about continuing, switching, or adding therapy.
Don't change anything based on your ratio alone. It's a signal — not a verdict.
Honest limitations
This was a biomarker analysis from a single Phase 2 trial. Sample sizes were relatively small, and the study wasn't designed to test NLR directly.
The findings are associations, not proof that changing NLR would change outcomes. Other factors like infection, stress, or medications can also shift NLR, which complicates interpretation.
Larger, prospective trials are needed to lock in NLR's role.
Researchers are also exploring whether combining NLR with PD-L1 and other markers can sharpen predictions. The long-term goal: a simple dashboard of easy-to-measure clues that helps tailor cancer treatment in real time.
For now, this study nudges NLR a bit closer to the clinic — and reminds us that even routine blood tests may hold more information than they've been given credit for.
